

ANTICIPATED ACQUISITION BY THERAMEX HQ UK LIMITED OF EUROPEAN RIGHTS TO VIATRIS INC'S FEMOSTON AND DUPHASTON PRODUCTS

06 February 2024

NOTICE UNDER SECTION 96(2A) OF THE ENTERPRISE ACT 2002 PUBLISHED PURSUANT TO SECTION 107(1)(I) OF THE ENTERPRISE ACT 2002

The Competition and Markets Authority (**CMA**) hereby gives notice pursuant to section 96(2A) of the Enterprise Act 2002 (the **Act**) that the merger notice provided by Theramex HQ UK Limited and Viatris Inc in relation to the anticipated acquisition by Theramex HQ UK Limited of the European rights to Viatris Inc's Femoston and Duphaston products (the **Transaction**) meets the requirements of section 96(2) of the Act.

The initial period defined in section 34ZA(3) of the Act in relation to the Transaction will therefore commence on the first working day after the date of this notice, ie on 7 February 2024. The deadline for the CMA to announce its decision whether to refer the Merger for a phase 2 investigation is therefore 4 April 2024